Do analysts recommend ANL or MESO?

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 89.16%. Given Adlai Nortye's stronger consensus rating and higher possible upside, equities research analysts plainly believe Adlai Nortye is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, ANL or MESO?

Adlai Nortye has higher earnings, but lower revenue than Mesoblast. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.56 -$35.53M N/A N/A Mesoblast $17.20M 115.72 -$102.14M -$0.28 N/A

Is ANL or MESO more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Mesoblast N/A N/A N/A

Does the media prefer ANL or MESO?

In the previous week, Mesoblast had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Mesoblast and 1 mentions for Adlai Nortye. Mesoblast's average media sentiment score of 0.36 beat Adlai Nortye's score of 0.19 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ANL or URGN?

Adlai Nortye has higher earnings, but lower revenue than Urogen Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.56 -$35.53M N/A N/A Urogen Pharma $109.79M 18.55 -$153.49M -$2.75 N/A

Is ANL or URGN more profitable?

Adlai Nortye has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Urogen Pharma -94.83% N/A -62.85%

Does the media prefer ANL or URGN?

In the previous week, Urogen Pharma had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Urogen Pharma and 1 mentions for Adlai Nortye. Urogen Pharma's average media sentiment score of 0.71 beat Adlai Nortye's score of 0.19 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ANL or NBTX?

Nanobiotix has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.56 -$35.53M N/A N/A Nanobiotix $36.87M 54.99 -$27.11M N/A N/A

Is ANL or NBTX more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Nanobiotix N/A N/A N/A

Does the media refer more to ANL or NBTX?

In the previous week, Nanobiotix had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Nanobiotix and 1 mentions for Adlai Nortye. Nanobiotix's average media sentiment score of 0.78 beat Adlai Nortye's score of 0.19 indicating that Nanobiotix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ANL or PVLA?

Adlai Nortye has higher earnings, but lower revenue than Palvella Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.56 -$35.53M N/A N/A Palvella Therapeutics $42.81M 47.01 -$41.72M -$4.17 N/A

Is ANL or PVLA more profitable?

Adlai Nortye's return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Palvella Therapeutics N/A -56.87% -42.50%

Does the media prefer ANL or PVLA?

In the previous week, Palvella Therapeutics had 10 more articles in the media than Adlai Nortye. MarketBeat recorded 11 mentions for Palvella Therapeutics and 1 mentions for Adlai Nortye. Palvella Therapeutics' average media sentiment score of 0.86 beat Adlai Nortye's score of 0.19 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ANL or SION?

Adlai Nortye has higher revenue and earnings than Sionna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 102.56 -$35.53M N/A N/A Sionna Therapeutics N/A N/A -$75.27M -$1.93 N/A

Is ANL or SION more profitable?

Adlai Nortye's return on equity of 0.00% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Sionna Therapeutics N/A -27.31% -25.88%

Does the media refer more to ANL or SION?

In the previous week, Sionna Therapeutics had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Sionna Therapeutics and 1 mentions for Adlai Nortye. Sionna Therapeutics' average media sentiment score of 0.86 beat Adlai Nortye's score of 0.19 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adlai Nortye (ANL) Competitors

$12.82 -0.40 (-3.03%)

As of 11:38 AM Eastern

Compare

ANL vs. MESO, URGN, NBTX, PVLA, and SION

Should you buy Adlai Nortye stock or one of its competitors? MarketBeat compares Adlai Nortye with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adlai Nortye include Mesoblast (MESO), Urogen Pharma (URGN), Nanobiotix (NBTX), Palvella Therapeutics (PVLA), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.

How does Adlai Nortye compare to Mesoblast?

Adlai Nortye (NASDAQ:ANL) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Mesoblast	N/A	N/A	N/A

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 89.16%. Given Adlai Nortye's stronger consensus rating and higher possible upside, equities research analysts plainly believe Adlai Nortye is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Adlai Nortye has higher earnings, but lower revenue than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.56	-$35.53M	N/A	N/A
Mesoblast	$17.20M	115.72	-$102.14M	-$0.28	N/A

In the previous week, Mesoblast had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Mesoblast and 1 mentions for Adlai Nortye. Mesoblast's average media sentiment score of 0.36 beat Adlai Nortye's score of 0.19 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Mesoblast beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Urogen Pharma?

Adlai Nortye (NASDAQ:ANL) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Adlai Nortye presently has a consensus price target of $24.25, suggesting a potential upside of 89.16%. Urogen Pharma has a consensus price target of $41.63, suggesting a potential downside of 0.44%. Given Adlai Nortye's higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Adlai Nortye has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Adlai Nortye has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Urogen Pharma	-94.83%	N/A	-62.85%

In the previous week, Urogen Pharma had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Urogen Pharma and 1 mentions for Adlai Nortye. Urogen Pharma's average media sentiment score of 0.71 beat Adlai Nortye's score of 0.19 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher earnings, but lower revenue than Urogen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.56	-$35.53M	N/A	N/A
Urogen Pharma	$109.79M	18.55	-$153.49M	-$2.75	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Urogen Pharma beats Adlai Nortye on 9 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Nanobiotix?

Adlai Nortye (NASDAQ:ANL) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 89.16%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 6.78%. Given Adlai Nortye's stronger consensus rating and higher possible upside, research analysts clearly believe Adlai Nortye is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Nanobiotix	N/A	N/A	N/A

Adlai Nortye has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Nanobiotix had 1 more articles in the media than Adlai Nortye. MarketBeat recorded 2 mentions for Nanobiotix and 1 mentions for Adlai Nortye. Nanobiotix's average media sentiment score of 0.78 beat Adlai Nortye's score of 0.19 indicating that Nanobiotix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nanobiotix has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.56	-$35.53M	N/A	N/A
Nanobiotix	$36.87M	54.99	-$27.11M	N/A	N/A

Summary

Nanobiotix beats Adlai Nortye on 6 of the 11 factors compared between the two stocks.

How does Adlai Nortye compare to Palvella Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Palvella Therapeutics (NASDAQ:PVLA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Adlai Nortye's return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Palvella Therapeutics had 10 more articles in the media than Adlai Nortye. MarketBeat recorded 11 mentions for Palvella Therapeutics and 1 mentions for Adlai Nortye. Palvella Therapeutics' average media sentiment score of 0.86 beat Adlai Nortye's score of 0.19 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher earnings, but lower revenue than Palvella Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.56	-$35.53M	N/A	N/A
Palvella Therapeutics	$42.81M	47.01	-$41.72M	-$4.17	N/A

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Adlai Nortye has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 89.16%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 42.17%. Given Adlai Nortye's higher possible upside, equities analysts clearly believe Adlai Nortye is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

Palvella Therapeutics beats Adlai Nortye on 8 of the 14 factors compared between the two stocks.

How does Adlai Nortye compare to Sionna Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Sionna Therapeutics (NASDAQ:SION) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Adlai Nortye's return on equity of 0.00% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Sionna Therapeutics	N/A	-27.31%	-25.88%

In the previous week, Sionna Therapeutics had 3 more articles in the media than Adlai Nortye. MarketBeat recorded 4 mentions for Sionna Therapeutics and 1 mentions for Adlai Nortye. Sionna Therapeutics' average media sentiment score of 0.86 beat Adlai Nortye's score of 0.19 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Sionna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	102.56	-$35.53M	N/A	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

35.2% of Adlai Nortye shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Adlai Nortye presently has a consensus target price of $24.25, suggesting a potential upside of 89.16%. Sionna Therapeutics has a consensus target price of $53.22, suggesting a potential upside of 16.47%. Given Adlai Nortye's higher possible upside, analysts plainly believe Adlai Nortye is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Adlai Nortye has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Summary

Sionna Therapeutics beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.80M	$3.65B	$6.88B	$12.20B
Dividend Yield	N/A	2.19%	2.68%	9.43%
P/E Ratio	N/A	21.50	26.92	23.72
Price / Sales	102.56	298.92	517.00	90.63
Price / Cash	N/A	156.74	50.43	59.93
Price / Book	-61.05	7.88	10.02	6.10
Net Income	-$35.53M	$23.81M	$3.60B	$331.84M
7 Day Performance	11.19%	-3.22%	-0.92%	-1.05%
1 Month Performance	16.65%	-3.09%	-0.25%	-2.60%
1 Year Performance	772.11%	32.72%	19.04%	13.86%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	1.7024 of 5 stars	$12.82 -3.0%	$24.25 +89.2%	+799.3%	$512.80M	$5M	N/A	127
MESO Mesoblast	0.7711 of 5 stars	$16.30 -0.7%	N/A	-0.1%	$2.11B	$17.20M	N/A	80
URGN Urogen Pharma	1.9572 of 5 stars	$42.06 -3.9%	$41.63 -1.0%	+127.8%	$2.05B	$109.79M	N/A	200	Analyst Forecast
NBTX Nanobiotix	1.9515 of 5 stars	$40.38 +2.4%	$37.33 -7.5%	+579.0%	$2.04B	$29.64M	N/A	100
PVLA Palvella Therapeutics	2.9603 of 5 stars	$142.18 -1.2%	$199.53 +40.3%	+272.7%	$2.04B	N/A	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 7/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. MESO, URGN, NBTX, PVLA, and SION

How does Adlai Nortye compare to Mesoblast?

Summary

How does Adlai Nortye compare to Urogen Pharma?

Summary

How does Adlai Nortye compare to Nanobiotix?

Summary

How does Adlai Nortye compare to Palvella Therapeutics?

Summary

How does Adlai Nortye compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. MESO, URGN, NBTX, PVLA, and SION

How does Adlai Nortye compare to Mesoblast?

Is ANL or MESO more profitable?

Do analysts recommend ANL or MESO?

Do insiders & institutionals have more ownership in ANL or MESO?

Which has better earnings and valuation, ANL or MESO?

Does the media prefer ANL or MESO?

Which has more volatility & risk, ANL or MESO?

Summary

How does Adlai Nortye compare to Urogen Pharma?

Do analysts prefer ANL or URGN?

Which has more volatility and risk, ANL or URGN?

Is ANL or URGN more profitable?

Does the media prefer ANL or URGN?

Which has preferable earnings and valuation, ANL or URGN?

Do insiders and institutionals hold more shares of ANL or URGN?

Summary

How does Adlai Nortye compare to Nanobiotix?

Do insiders & institutionals hold more shares of ANL or NBTX?

Do analysts rate ANL or NBTX?

Is ANL or NBTX more profitable?

Which has more risk and volatility, ANL or NBTX?

Does the media refer more to ANL or NBTX?

Which has preferable valuation & earnings, ANL or NBTX?

Summary

How does Adlai Nortye compare to Palvella Therapeutics?

Is ANL or PVLA more profitable?

Does the media prefer ANL or PVLA?

Which has better valuation & earnings, ANL or PVLA?

Do insiders and institutionals have more ownership in ANL or PVLA?

Which has more risk & volatility, ANL or PVLA?

Do analysts recommend ANL or PVLA?

Summary

How does Adlai Nortye compare to Sionna Therapeutics?

Is ANL or SION more profitable?

Does the media refer more to ANL or SION?

Which has stronger earnings & valuation, ANL or SION?

Do institutionals and insiders have more ownership in ANL or SION?

Do analysts recommend ANL or SION?

Which has more volatility and risk, ANL or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools